June 12, 2018 03:29 AM EDT

PhIII Alzheimer’s drug goes bust — and a major setback at Eli Lilly and AstraZeneca may doom the class

John Carroll

Editor & Founder

Another big Phase III Alzheimer’s program is being scrapped at Eli Lilly $LLY and AstraZeneca $AZN, offering fresh evidence that the entire BACE class may …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

PhIII Alzheimer’s drug goes bust — and a major setback at Eli Lilly and AstraZeneca may doom the class

John Carroll

Editor & Founder

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

PhI­II Alzheimer’s drug goes bust — and a ma­jor set­back at Eli Lil­ly and As­traZeneca may doom the class

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

PhIII Alzheimer’s drug goes bust — and a major setback at Eli Lilly and AstraZeneca may doom the class

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market